Neoantigen pioneer Neon Therapeutics casts off in search of $115M IPO to fuel the race to a personalized cancer treatment
Can a bespoke cancer vaccine actually succeed in treating individual oncology cases?
Neon Therapeutics launched three years ago, setting out on a mission to prove that it could, and it now has enough examples of a select handful of individual responses to their neoantigen platform to gamble that investors will come in to back a $115 million IPO as they look to transition from their first exploratory human studies into advanced development work.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.